Podcasts about Novartis

In this episode, I share my preview of the hot topics for the upcoming AAO 2022 annual meeting, including my thoughts on ocular gene therapy and new treatments in the works. Welcome to another exciting episode of Eye Care insider :52 My preview of hot topics for the upcoming AAO 2022 annual meeting 1:04 Hot Topic #1 – new treatments for dry AMD or geographic atrophy 2:43 Hot Topic #2 – wet AMD management 5:55 Hot Topic #3 – ocular gene therapy 7:56 Hot Topic #4 – biosimilars 9:17 Thanks for listening 11:22 We'd love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

Bill George: True North Bill George is executive fellow at Harvard Business School, where he has taught leadership since 2004. He is the author of four best-selling books: Authentic Leadership, True North, Discover Your True North, and 7 Lessons for Leading in Crisis. He was chair and CEO of Medtronic, the world's leading medical technology company. Under his leadership, Medtronic's market capitalization grew from $1.1 billion to $60 billion, averaging 35 percent a year. Bill has served as a director of Goldman Sachs, ExxonMobil, Novartis, Target, the Mayo Clinic, and World Economic Forum USA. He has been named one of the Top 25 Business Leaders of the Past 25 Years by PBS, Executive of the Year by Academy of Management, and Director of the Year by National Association of Corporate Directors. He is the author with Zach Clayton of True North: Leading Authentically in Today's Workplace, Emerging Leader Edition*. We've all seen leadership go badly and most of us struggle with tendencies to get pulled off course. In this conversation, Bill and I explore the five most common archetypes that tend to derail leaders and the antidote that prevents them. We also discuss how we can recognize these tendencies in ourselves so that we can do better for others. Key Points Five archetypes of leadership derailment: Imposters: political animals who figure out who their competitors and then eliminate them. Rationalizers: masters of denial who don't take responsibility themselves. Glory seekers: motivated by the acclaim of the world. Loners: they believe they can make it on their own and reject feedback. Shooting stars: they build shallow foundations and move on quickly to the next things, often avoiding commitment. Antidotes to leadership derailment: Write down the most difficult ethical dilemma you are currently facing and chronicle the “least generous” interpretation of your actions. Project forward a decade and assume the worst: you have derailed in a major failure. Envision the situation in which you could lose your way. Resources Mentioned True North: Leading Authentically in Today's Workplace, Emerging Leader Edition* by Bill George and Zach Clayton Interview Notes Download my interview notes in PDF format (free membership required). Related Episodes Discover Your True North, with Bill George (episode 225) Leadership Lies We Tell Ourselves, with Emily Leathers (episode 479) How to Help Your Manager Shine, with David Gergen (episode 588) Discover More Activate your free membership for full access to the entire library of interviews since 2011, searchable by topic.

Comment évaluer la nécessité d'une prothèse chez un patient gonarthrosique ? Quel est le meilleur moment pour adresser un patient au chirurgien et selon quelle imagerie ? Quel conseil donner aux auditeurs ?   Le Pr Francis Berenbaum, rhumatologue au sein du service de Rhumatologie de l'Hôpital Saint-Antoine à Paris, et responsable de l'équipe « Pathologies articulaires associées aux maladies métaboliques et à l'âge » au Centre de recherche Saint Antoine, répond à vos questions.   Invité : Pr Francis Berenbaum – Hôpital Saint Antoine – Paris https://www.aphp.fr/service/service-38-073  https://www.crsa.fr/equipe-francis-berenbaum.html  Le Pr Berenbaum déclare des liens d'intérêts avec les laboratoires 4P PHARMA, 4Moving Biotech, Boehringer Ingelheim, Bone Therapeutics, CellProthera, Expanscience, Galapagos, Gilead, GSK, Lilly, Merck, Novartis, Pfizer, Servier, Peptinov.   L'équipe :
 Comité scientifique : Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud-Listrat, Dr Céline Vidal, Dr Sophie Hecquet Animation :  Pyramidale Communication Production : Pyramidale Communication Soutien institutionnel : Pfizer   Crédits : Pyramidale Communication, Sonacom

I'm thrilled to be launching my partnership with BEworks today. Co-founded by Dan Ariely and Nina Mazar (previous guest on the show alongside Dilip Soman), BEworks is a multidisciplinary team of behavioural scientists and psychologists working on complex challenges across financial services to healthcare to sustainability, helping businesses reimagine a future in which individuals flourish and prosper.And so today starts a 10-part series of short, sharp and very digestible conversations with practitioners at the heart of the action; from Coca-Cola to Novartis to Natwest Bank to the World Bank.But today, I'm delighted to be kicking off by talking to BEwork's new CEO Wardah Malik.Show notesHow does BEworks approach client challengesWork Wardah is most proud ofCreating, sustainable behavioural change at scaleBEworks's Reimagining strategyDiversity of talent in behavioural scienceWhat skills are needed to be a successful behavioural scientist?The different languages of behavioural scienceThe next frontier: what does better access to data and AI mean for behavioural scienceThe intersection of behavioural science and cognitive technologyBehavioural science is like the Wild WestSubscribe for more hereClick here to access rewards to power your brainFollow me on Twitter

Host: Anisha Dua, MD, MPH Guest: Michael Putman, MD, MSci What does the therapeutic landscape look like for patients with giant cell arthritis (GCA)? Joining Dr. Anisha Dua to highlight the need for more targeted therapies is Dr. Mike Putman from the Medical College of Wisconsin. Dr. Dua and Dr. Putman are Novartis consultants. 199849 6/22

Life is about events, the challenges we overcome or not, our successes and failures, but, even more, it's about how we touch and are touched by the people we meet.  Nicole is back! She is here this week to help me answer your listener questions. In this episode, we discuss the challenges of making friends in retirement, the value of international diversification, contributing to a Roth 401K vs. a regular 401K, the 4% rule, and much more.  I created the Retirement Answer Man show to help you, not just with the business side of retirement, but also to help you build a successful life so that you can lean in and really rock retirement. This month we are answering your retirement questions. If you have a question to submit, head on over to RogerWhitney.com/AskRoger to proffer your questions. Remember, if you want to get bumped to the front of the line and use our fastpass option by recording an audio question.  Check out these resources to learn more about inflation in retirement and the RRC Have you been thinking about joining the Rock Retirement Club? If so, sign up for our updates so that you can be the first to learn about the next online open house. We'll be opening enrollment at the end of October and plan to have a few open house opportunities between now and then. These open houses will be an informative way to for you to learn more about the club so that you can decide whether it is right for you.  Are you worried about inflation in retirement? If so, we have created a resource to help you navigate this worrisome hurdle. Check out DoRetirementRight.com to get this FREE information to help you think strategically about inflation in retirement.  Trying to make friends as a single person in retirement can be a challenge In many 55+ communities, it is pretty easy to make new friends. Everyone is a transplant from somewhere else and there are endless opportunities to join activities and clubs.  However, if you are single it may not be as easy as it is if you are married. Many retirement activities are geared toward couples so single people can have a harder time getting invitations.  Are you single in retirement? What strategies have you implemented to help you make friends? Reply to the 6-Shot Saturday newsletter with your suggestions.  Why keep international equities? Many people wonder what the point of keeping international equities in a portfolio is. It seems as though global equities fall at the time when we need them to be stable or growing, so why bother to include them in our portfolios? Traditionally, they do poorly as compared to other markets, yet including international equities is recommended as a part of having a diversified portfolio strategy.  I tend to recommend international equities, not for diversification, but for the fact that many fantastic companies aren't based in the U.S. Think about Toyota, Mercedes, Glaxo, Novartis, and even Ikea. Rather than considering a different asset class to add to your portfolio, choose the best worldwide companies to expand your portfolio to include top-notch mid to large-cap international companies.  OUTLINE OF THIS EPISODE OF THE RETIREMENT ANSWER MAN PRACTICAL PLANNING SEGMENT [5:23] On making friends [8:23] The value of international diversification LISTENER QUESTIONS [12:05] Should I contribute to my Roth 401K or just a 401K near retirement [16:12] Are investment advisor fees worth it? [26:00] Why haven't I heard back from the IRS? [29:06] Where do my 401K profits go when inflation goes up? [32:33] How does the 4% rule apply to dividends? [35:22] Is 15% enough to save for retirement? [37:20] Why is there a disclaimer about indices at the end of the show? TODAY'S SMART SPRINT SEGMENT [40:43] Be inclusive make an effort to reach out to new people you meet Resources Mentioned In This Episode Rock Retirement Club DoRetirementRight.com Roger's YouTube Channel - Roger That BOOK - Rock Retirement  by Roger Whitney Roger's Retirement Learning Center

This week's episode features a fascinating conversation with Samin Saeed, UK Chief Scientific Officer and Medical Director at Novartis UK. She discusses a whole host of medical affairs-related issues, including the transition from medicine to pharma, cross-functionality, commercial versus medical affairs, and lots more besides, including a fascinating discussion about leadership, company culture and soft skills development. And ‘news you might have missed' focuses on the European life sciences gender pay gap and new investment for Novartis.   If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Preparing MSLs for the spotlight https://www.emg-gold.com/post/preparing-msls-for-the-spotlight Juby Jacob-Nara on medical affairs https://www.emg-gold.com/post/juby-jacob-nara-on-medical-affairs Aliya Omer on gender equality https://www.emg-gold.com/post/podcast-aliya-omer-on-gender-equality Reframing pharma's bad boy reputation https://www.emg-gold.com/post/reframing-pharma-s-bad-boy-reputation Elevating pharma's parental leave policies https://www.emg-gold.com/post/elevating-pharma-s-parental-leave-policies

My guest today is Bill George, an executive fellow at Harvard Business School, where he has taught leadership since 2004. He was chair and CEO of Medtronic, was an executive with Honeywell and Litton Industries, and has served in the U.S. Department of Defense. He has served as a director of Goldman Sachs, ExxonMobil, Novartis, Target, the Mayo Clinic, and World Economic Forum USA. He received the 2014 Bower Award for Business Leadership and was elected to the National Academy of Engineering in 2012. The topic is his book True North: Leading Authentically in Today's Workplace. In this episode of Trend Following Radio we discuss: Today's world leaders Social networks and Facebook chaos The essence of True North What led Bill to his career? Investment knowledge from Warren Buffett Bill's core philosophy A message to emerging leaders in the making Jump in! --- I'm MICHAEL COVEL, the host of TREND FOLLOWING RADIO, and I'm proud to have delivered 10+ million podcast listens since 2012. Investments, economics, psychology, politics, decision-making, human behavior, entrepreneurship and trend following are all passionately explored and debated on my show. To start? I'd like to give you a great piece of advice you can use in your life and trading journey… cut your losses! You will find much more about that philosophy here: https://www.trendfollowing.com/trend/ You can watch a free video here: https://www.trendfollowing.com/video/ Can't get enough of this episode? You can choose from my thousand plus episodes here: https://www.trendfollowing.com/podcast My social media platforms: Twitter: @covel Facebook: @trendfollowing LinkedIn: @covel Instagram: @mikecovel Hope you enjoy my never-ending podcast conversation!

My guest today is Bill George, an executive fellow at Harvard Business School, where he has taught leadership since 2004. He was chair and CEO of Medtronic, was an executive with Honeywell and Litton Industries, and has served in the U.S. Department of Defense. He has served as a director of Goldman Sachs, ExxonMobil, Novartis, Target, the Mayo Clinic, and World Economic Forum USA. He received the 2014 Bower Award for Business Leadership and was elected to the National Academy of Engineering in 2012. The topic is his book True North: Leading Authentically in Today's Workplace. In this episode of Trend Following Radio we discuss: Today's world leaders Social networks and Facebook chaos The essence of True North What led Bill to his career? Investment knowledge from Warren Buffett Bill's core philosophy A message to emerging leaders in the making Jump in! --- I'm MICHAEL COVEL, the host of TREND FOLLOWING RADIO, and I'm proud to have delivered 10+ million podcast listens since 2012. Investments, economics, psychology, politics, decision-making, human behavior, entrepreneurship and trend following are all passionately explored and debated on my show. To start? I'd like to give you a great piece of advice you can use in your life and trading journey… cut your losses! You will find much more about that philosophy here: https://www.trendfollowing.com/trend/ You can watch a free video here: https://www.trendfollowing.com/video/ Can't get enough of this episode? You can choose from my thousand plus episodes here: https://www.trendfollowing.com/podcast My social media platforms: Twitter: @covel Facebook: @trendfollowing LinkedIn: @covel Instagram: @mikecovel Hope you enjoy my never-ending podcast conversation!

Jamil Rivers returns to the podcast to talk about code switching in health care, ongoing disparities that are causing actual harm, and her work in connecting people to the standard of care in cancer care. ********** Find Jamil's organization here: www.thechrysalisinitiative.org www.bcnavi.com ********** Continue the conversation with us in the Healwell Community: community.healwell.org ********** Let us know what you think! Email us at podcast@healwell.org ********** About Our Guest: Jamil is Board President of METAvivor Research and Support, Inc. She is a Young Advocate Alum, Board Member of Living Beyond Breast Cancer and Advisory Chair of the Knowledge is Power: Understanding Black Breast Cancer series. She is a policy science and health equity advocate and metastatic advisory committee member with Susan G. Komen. In addition, she is a member and patient advisor of the Metastatic Breast Cancer Alliance. Jamil is also a Project LEAD graduate and proposal reviewer for the Breast Cancer Research program with the Department of Defense. Jamil also testified to the FDA in order to connect many women with resources for screenings, treatment, and support. She has been featured in People Magazine, the Philadelphia Inquirer, the Philadelphia Tribune, national campaigns for Anthropologie, Novartis, Pfizer and Cancer and Careers, as well as on CBS News and Good Morning America.

This episode is brought to you by Provider Solutions and Development, the leaders in physician and APC recruitment that deliver top-tier candidates for the right roles. Visit info.PSDconnect.org/outcomesrocket to start the conversation today, and get tailored support, dedicated recruitment, and efforts that lead to provider retention and longevity. Welcome to the weekly summary of what happened this week in the Outcomes Rocket Network! We got incredible episodes, and here's what we got: On our main channel, the Outcomes Rocket Podcast, Saul had Jason Hannon, executive director, and CEO at Mainstay Medical, talk about ReActiv8, a new groundbreaking therapy approach to help patients with back pain. Listen to it here: bit.ly/JasonHannon For Marketing Mondays, Andreea Borcea interviewed Brian Maurer, co-founder of Bristle Health. They talked about how Bristle makes oral microbiome tests to facilitate taking care of your own oral health, highlighting its importance, and why it's been a marketing challenge for them. Tune in to that episode here: http://bit.ly/MM-BrianMaurer The SONSIEL Podcast, welcomed Andrea Jaramillo, a hospice nurse, forest therapy guide, and nurse farmer. In this episode, they discussed finding what nursing means to you and designing a career that is sustainable for yourself and that makes you happy. Listen here: https://lnkd.in/gRzF2vyC The Sempre Health Podcast, hosted by Kyle Wildnauer-Haigney, had Bharti Rai, Vice President of Commercial Excellence, Insights, and Analytics at Novartis. They talked about how pharma as an industry has got to look at healthcare as a whole as opposed to medication only. Tune in to listen here: bit.ly/SEMPRE-BhartiRai On the Future of Global Informatics, host TJ Southern, interviewed Madeline Stadler, a nurse at Duke University Hospital. Madeline reflected on her education and highlights the importance of knowledge application and practice in the field. Listen to it here: https://lnkd.in/dQvgf4Ss LabOps Leadership Podcast, hosted by Samantha Black, invited Larina Burke, Laboratory Manager at Hyasynth Bio. They talked about her role as a laboratory manager in a small company, how Hyasynth Bio is the only company that produces a CBD isolate from yeast fermentation, and how being a part of the LabOps Unite Community has opened up many new opportunities for her. Tune in here: bit.ly/LabOps-LarinaBurke We had another episode on our main channel, the Outcomes Rocket Podcast, Saul had Tony Benedict, CEO at Omicron Partners. He talked about how the fundamental business model for delivering patient care has not changed in about half a century and why the healthcare industry is about 20 years behind other industries from both a technology and operations perspective. Listen here: http://bit.ly/TonyBenedict Tune in every week to discover something new about this industry! See you next week! Click this link to the show notes, transcript, and resources: outcomesrocket.health

Quelle(s) définition(s) de la Polyarthrite Rhumatoïde difficile à traiter ? Comment se présente la Polyarthrite Rhumatoïde difficile à traiter ? Quel impact a-t-elle dans la pratique en rhumatologie ? Comment adapter les interventions thérapeutiques en fonction des différents types de diagnostics ? Quel conseil donner aux auditeurs ?   Le Pr Jérôme Avouac, rhumatologue au sein du service de Rhumatologie de l'Hôpital Cochin à Paris, et chercheur INSERM à l'Hôpital Cochin, répond à vos questions.   Invité : Pr Jérôme Avouac – Hôpital Cochin – Paris https://www.cochin-poa.com/les-services/rhumatologie/  Le Pr Avouac déclare des liens d'intérêts avec les laboratoires Pfizer, Bristol Myers Squibb, UCB, Roche, Nordic, Novartis, Sanofi, Boehringer, Abbvie, Chugai, Galapagos, Biogen, Fresenius Kabi, Sandoz.   L'équipe :
 Comité scientifique : Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud-Listrat, Dr Céline Vidal, Dr Sophie Hecquet Animation :  Pyramidale Communication Production : Pyramidale Communication Soutien institutionnel : Pfizer   Crédits : Pyramidale Communication, Sonacom

Basel-Stadt erwartet für das kommende Jahr einen Überschuss von 66 Millionen Franken.  Ausserdem: * Hausdurchsuchung bei Novartis in Basel * Provenienzforschung wird in Basel verstärkt

Host: Ethan Craig, MD, MHS Guest: Alexis Ogdie-Beatty, MD, MSCE How does preclinical psoriatic arthritis (PsA) progress into chronic PsA? To dive into this path of progression, Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania. Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants. 221663 7/22

Die Wettbewerbskommission führt Hausdurchsuchung bei Novartis in Basel durch. Laut Direktor der Wettbewerbskommission (Weko), Patrik Ducrey, steht Novartis in Verdacht, ein Patent missbräuchlich eingesetzt zu haben. Noch ist es nur ein Verdacht, bei den Anlegern kam dies dennoch nicht gut an. SMI: -0.1%

Gastrointestinal cancer experts Dr. Aparna Parikh and Dr. Kristin Ciombor discuss the treatment implications of the phase 3 PARADIGM trial and other advances in colorectal cancer with guest host and ASCO Daily News Associate Editor, Dr. Shaalan Beg.   TRANSCRIPT Dr. Shaalan Beg: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg, your guest host of the ASCO Daily News Podcast today. I'm an adjunct associate professor at UT Southwestern's Simmons Comprehensive Center and vice president of Oncology at Science 37. I'm delighted to welcome Dr. Aparna Parikh, and Dr. Kristen Ciombor to the podcast today. Dr. Parikh is an assistant professor of Medicine at Harvard University and a GI medical oncologist at the Mass General Hospital Cancer Center. Dr. Ciombor is an associate professor of Medicine and GI medical oncologist at the Vanderbilt University Medical Center. Today, we'll be discussing exciting new approaches using EGFR inhibitors as frontline therapy in colorectal cancer, and promising advances with immune therapy in the treatment of rectal cancer. Our full disclosures are available in the show notes, and disclosures of all guests on the podcast can be found in our transcripts at: asco.org/podcasts. Dr. Parikh, and Dr. Ciombor, it's great to have you on the podcast today. Dr. Aparna Parikh: Thanks so much. Dr. Kristen Ciombor: Thanks so much for having us. Dr. Shaalan Beg: We've seen some exciting advances in GI oncology this year. Let's start with colorectal cancer. Dr. Parikh, there have been many trials looking to compare EGFR and VEGF inhibitors in colorectal cancer. We've heard about the IDEA studies, the FIRE trials, and CALGB 80405. At the 2022 ASCO Annual Meeting, we heard the results of the PARADIGM trial. Have we finally answered the question of when to use EGFR inhibitors as frontline therapy for colorectal cancer? Dr. Aparna Parikh: Thanks so much, Dr. Beg, for this great question. It has been a really exciting year for colorectal cancer across the board. So, the anti-EGFR story is really interesting and has evolved. And maybe just for a little bit of background, we know that colorectal cancer originating from both the right and left side of the colon differ. So, they differ embryologically, and epidemiologically; there are different genetic and molecular aspects to right and left sides of colon cancers. And we have learned over time that in the era of targeted therapy, the primary tumor location has been found to play a very important role, not only in the prognosis of patients but to predict treatment response. We know that patients that have left-sided colon cancers-- and when we think about left-sided colon cancers, we think about cancers that originate from the splenic flexure and descending colon, sigmoid colon, rectosigmoid junction, and sometimes include the rectum in this as well. The rectals have slightly different molecular features than distal colons. And we know that these left-sided patients, overall, have better survival benefits than patients that have right-sided CRC. And that includes again, cecum, ascending colon, hepatic flexure, and transverse colon. So, we know that that had prognostic implications, but what about the predictive implications? And with ASCO, we saw some really exciting data with the PARADIGM study, as Dr. Beg highlighted. We have seen many examples in the past showing the predictive power of anti-EGFR therapy, and anti-EGFR therapy showing a detriment for patients on the right side of the colon. But all these results historically have been obtained by retrospective analysis. So, retrospective analysis of the pivotal CALGB 80405 study, which is the first-line biologic trial. FIRE-3, which is a similar study, but done out of Europe, and KRYSTAL. So all these studies show the same finding but were all obtained basically by retrospective analysis. And what we saw with PARADIGM this year, which is exciting to see, is that this was the first prospective trial to test the superiority of an anti-EGFR inhibitor panitumumab versus bevacizumab in combination with standard doublet first-line chemotherapy for patients that were RAS-wild type. I guess I forgot to mention that again, anti-EGFR therapies are only eligible for patients that are RAS-wild type. We know that RAS-mutant patients and RAS, KRAS HRAS patients don't respond to anti-EGFR therapy. So, the study was looking at RAS-wild type patients, and again, asking the question “was panitumumab better than bevacizumab in combination with chemotherapy for these RAS-wild type patients and for left-sided tumors?” It was a multicenter trial done in Japan-- and I always commend the Japanese on their work and their designs and ability to do these studies that ask really important questions. And, overall survival was the primary endpoint of the study in patients with left-sided tumors, but they also did a full set analysis including patients that didn't have left-sided tumors. They had 823 randomized patients. Many patients, a handful did not receive per-protocol treatment, and some were excluded for other reasons relating to inclusion criteria. And they had 400 patients that ultimately received panitumumab and 402 patients that received bevacizumab in the full set analysis. And of those patients, there were 312 and 292 respectively had left-sided tumors. And although the PFS was comparable between the treatment group, we saw that panitumumab in the left-sided patients actually did improve the OS in both patient populations. But when you looked at the left-sided tumors, the difference was 37.9 versus 34.3 months meeting statistical significance. So, this was an exciting study because it confirmed prospectively what we have seen time and time again, and really behooves us to do early biomarker testing and know RAS status early for these patients with right-sided tumors, as they do derive benefit from anti-EGFR. Maybe I'll just pause there and open it up for more questions or comments from Dr. Ciombor as well. Dr. Kristen Ciombor: Yeah, Dr. Parikh, I thought these data were encouraging. And as you mentioned, the first prospective data that we have in this setting now that we know this primary tumor sidedness matters. Just on a practical note, what do you do in practice? Do you give a lot of anti-EGFR in the first-line? I find that the toxicity can be challenging sometimes and patients may not want to do that. So, it leaves us in a quandary sometimes. Dr. Aparna Parikh: Yeah. So, what's interesting and I don't think we have this data clearly answered yet is, I had, especially for kind of a fit patient-- with the previous data that we've seen with TRIBE and others showing a survival benefit with triplet chemotherapy for first-line therapy, my inclination had actually been to prefer triplet-- and we know that triplet and anti-EGFR toxicity-wise is really, really tough to manage, and really no benefit there that we've seen with OS or PFS, even though you maybe do get a little bit of a better response rate with that. And so where I have sort of struggled is triplet versus just doing first-line doublet plus anti-EGFR. You know, we are not having a discussion about triplet today, but we also saw some data at ASCO showing that perhaps the benefit of the triplet, with the triplet study, is not as much as we had hoped it would've been too. So, it's a good question. I do tend to prefer triplet, I guess, overall, for the healthy, good performance status patient. And then, if not, then doublet. And we, unfortunately, don't have kind of rapid EGFR testing, we're pushing for that. In practice, I think having RAS/RAF status up front would be entirely helpful. It's lumped into our pan-tumor profiling, comprehensive genomic panels. We get microsatellite instability (MSI) status, which I know we'll talk about here next right away. But I think another reason that oftentimes we don't add it right away, is because we don't have the RAS status right away. So, you just start with a doublet and you may end up sneaking it on later. And then, I'd love to, maybe in another podcast, where we can discuss second-line anti-EGFR therapies and what people do in practice for those right-sided patients should they never get anti-EGFR and later-lines of therapy too. And I would argue, perhaps not, because we do see some patients that do benefit, but it can be challenging sometimes with a fresh new patient to make these decisions. But at least, feel encouraged that we're doing the right thing by adding anti-EGFR therapy if they can tolerate it for the left-sided RAS-wild type patient. How about you? What do you do? Dr. Kristen Ciombor: Yeah. Largely, it's a great question. And I don't love giving anti-EGFR therapy. We have an additional issue where I am geographically in that we don't ever give cetuximab because of the high rates of an infusion reaction. So, we pretty much stick to panitumumab and are glad to have that option. But I have started to talk to patients about toxicity and I'm really upfront with the survival data. And it's interesting how people choose differently in terms of what's important to them. And whereas a few extra months in the overall survival may be overshadowed by the toxicity that they have to go through to accomplish that. So, it's good to have many options though, and that's the important thing, and I think the takeaway, as well. Dr. Shaalan Beg: So, kind of brings it back to the fundamentals of practicing medicine, right? Bringing our patients and giving them the options that are most available to them. But I'm going to ask both of you one by one: So, if we have our patient with left-sided colorectal cancer, known as KRAS RAS-wild type, do you recommend EGFR therapy and VEGF therapy and allow the patients to decide, or do you feel that we decide if their profile is such that we should continue with VEGF therapy instead? Dr. Ciombor, do you want to go first? Dr. Kristen Ciombor: Yeah, I think both are good options. I don't only do bevacizumab in the first-line by any means because we do have that survival data. It mostly comes down to a discussion with the patient in terms of toxicities and survival and how well those balance out. Dr. Aparna Parikh: Yeah, very similar. I think we have also gotten a little bit more adept at managing toxicity. I'm pretty aggressive about prophylaxis with even doxy and topicals for managing the rash. And so, for some of my younger patients who are wanting to be "aggressive" and want the exposure to anti-EGFR early but are still very mindful of how it's impacting their day-to-day semblance of self, especially for the younger patients, try to be very proactive about side effect management. And then, of course, we have the patients that have the electrolyte wasting and things too that sometimes if it's bad, we are stuck with infusions frequently and you may end up dropping for those patients. But I think the rash at least I feel like for most patients we can manage if you're aggressive about it too. And I think we have gotten better at that than we were many years ago. Dr. Kristen Ciombor: Never thought we'd be dermatologists, did we? In training, that was definitely not a path I was good at. Dr. Shaalan Beg: Dermato-Oncology, rapidly growing field. So, Dr. Ciombor, the rectal cancer space has evolved very rapidly in recent years, especially when we hear about total neoadjuvant therapy, short-course radiation, watch-and-wait, for those with complete clinical responses. So at ASCO this year, we heard results on immune therapy and rectal cancer. Can you summarize where we are with immune therapy and rectal cancer? Dr. Kristen Ciombor: So, yes. We heard a lot this year at ASCO; both at ASCO GI and ASCO, from the Memorial group and Dr. Cercek's group. And this has been a really exciting advance that we're starting to see and potentially paradigm-shifting data. So, we know-- as you mentioned, that our treatment of rectal cancer, specifically, locally advanced rectal cancer has changed a lot in the last few years with a shift to more Total Neoadjuvant Therapy. And what the Memorial data showed was that for the patients who have microsatellite instability or mismatch repair deficiency, which admittedly, is a small group, but certainly ones that we see in clinic, those patients, on their trial were treated with six months of dostarlimab as neoadjuvant therapy prior to any other treatment; before radiation, surgery, et cetera, and no chemotherapy. And what they found was that actually, six months of dostarlimab in the first 14 evaluable patients actually induced a 100% clinical complete response rate. So, it's really unheard of in most of our trials to see 100%. And I think that caught everyone's attention for sure. I think we have to keep in mind who these patients were and are because they are currently being followed. So, for instance, these were patients that had pretty bulky node-positive disease, almost all these patients did. These were not really early-stage tumors. We did see that 100% were BRAF-wild type, so it does tell us maybe this is not completely the population that we're all seeing when we do see microsatellite instability since we see a lot of sporadic tumors with BRAF mutations. But on the whole, I mean, these were all MSI-high patients and treated with dostarlimab; the six months, that was the total amount of treatment that they received, though a few patients achieved that clinical complete response earlier at about three months, at the three-month reassessment. And what the clinical complete response rate was, was looking both radiographically, as well as endoscopically, and not seeing any sign of residual tumor. I think the important thing here is that median follow-up is still pretty short. There are a few patients who are approaching now two years past that dostarlimab therapy and have not had tumor recurrence, but overall, the median follow-up is still quite short. So, I think we do need to continue to follow these patients. We don't have overall survival data yet either. I think we still have a lot to learn, but this is a very encouraging start and certainly, something that could be really treatment-changing for these patients, which again, as Dr. Parikh was saying, we need this molecular profiling early to make treatment decisions right off the bat, not even only for metastatic now, but even for these locally-advanced rectal cancer patients. Because if you think about it, we've all taken care of patients who have to go through chemoradiation, and chemo, and surgery, and have a lot of morbidity from those treatments so that even if you cure them, they're left with a lot of toxicity. So, if we could avoid some of that, even potentially, surgery, that would be wonderful. But I do caution that this is not the standard of care yet. This is only based on 14 patients with short follow-ups at the current time. But the trial is ongoing, and there are other trials open in this space for patients who don't live in New York or can't get to New York. And for instance, ECOG-ACRIN study 2201 is treating these same patients with nivo and ipi, as opposed to dostarlimab. And that trial is open in about 80 sites now across the US. So hopefully, geographically near all of these patients. Dr. Shaalan Beg: I think a lot of us and a lot of our listeners, that Monday after the results were announced on ASCO had our phone lines and our patient secure messaging lines blowing up. Dr. Kristen Ciombor: We should have warned our nurses and our treatment teams that they would be fielding these questions, yes. On one hand, it's wonderful that our data and the science is getting out to patients. But I think we also have to be really careful as to what is reaching them because many of them didn't realize it was for this subset of patient populations. But great that they're asking those questions and wondering-- being advocates for themselves too. Dr. Shaalan Beg: You use the term clinical complete response. Can you talk about how we determine someone has a complete clinical response and what their follow-up looks like? Dr. Kristen Ciombor: Yeah. In the context of this study, it was actually, as I mentioned, it was both radiographic complete response, as well as endoscopic. So that's one thing that is a little bit tricky when you think about surveillance of these patients. So, it requires a lot, both in frequent surveillance, MRIs, FLEX SIGs often, digital rectal exams, sometimes doing PET scans or CTs, and patients who-- not only on this kind of study but also in non-operative management; watch-and-wait - really have to commit to very close, very frequent follow-up because if the cancer recurs, we don't want to miss that and lose our chance to cure them. So I think that's a little bit different everywhere, how that watch-and-wait approach really manifests, but I think we're learning how to do that, and working in a multidisciplinary group to make sure that patients get the surveillance that they need. Dr. Aparna Parikh: Yeah. I totally agree. If we offer, for the MSI-high patients, if we ultimately end up offering neoadjuvant immunotherapy-- and actually, I'm looking forward to your study, Dr. Ciombor, too, I think the monotherapy versus doublet, too, is going to come up for these patients. But I had a patient just a week or two ago that was starting on this approach with neoadjuvant immunotherapy, but for now, as a group, if we're proceeding down that and they do get a clinical complete response, we're deciding to forego even the radiation and surgery. We're following what they did in the OPRA study, which was pretty aggressive surveillance on the backend, both with direct visualization and MRIs, and you're seeing these patients every three months or so. Dr. Shaalan Beg: Well, thank you Dr. Ciombor and Dr. Parikh for sharing some valuable insights with us on the podcast today. Dr. Aparna Parikh: Thanks so much for having us. It was a lot of fun. Dr. Kristen Ciombor: Thanks for having us on. Dr. Shaalan Beg: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Kristen Ciombor @KristenCiombor Dr. Aparna Parikh @aparna1024   Dr. Shaalan Beg @ShaalanBeg Listen to additional episodes on advances in GI oncology: Novel Therapies in GI Oncology at ASCO22 ASCO22: Key Posters on Advances in GI Oncology Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Shaalan Beg: Employment: Science 37 Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals Dr. Kristen Ciombor: Consulting or Advisory Role: Merck, Pfizer, Lilly, Seagen, Replimune, Personalis Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi Recipient, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calithera, Genentech, Seagen Travel, Accommodations, Expenses Company: Array Dr. Aparna Parikh: Stock and Ownership Interests: C2i genomics Consulting or Advisory Role: Eli Lilly, Natera, Checkmate Pharmaceuticals, Pfizer, Roche/Genentech, Inivata, Biofidelity, Guardant Health Research Funding(Inst.): PMV Pharma, Plexxikon, Bristol-Myers Squibb, Genentech, Guardant Health, Array, Eli Lilly, Novartis Pharmaceuticals UK Ltd., PureTech, Mirati Therapeutics, Daiichi Sankyo

Paul Capon // Xiong Liu https://www.linkedin.com/in/paulcapon11/

Pharma as an industry has got to look at healthcare as a whole instead of medication only. In this episode, Bharti Rai, Vice President of Commercial Excellence, Insights, and Analytics at Novartis, talks about how digital transformation in pharmaceuticals and life sciences can improve healthcare outcomes beyond the medications themselves. She talks about how data insights and analytics can refine the journey for both customers and providers by orienting care around the patients driven by the available data. Bharti speaks about how pharma is well-positioned to add value to the healthcare ecosystem from its financial standpoint and its wide range of possibilities with patient care “beyond the pill.” She shares a setback she had when integrating her personal life with work and how that could be a behavioral mindset issue, just like some problems patients face. Tune in to this episode to listen about disruption and transformation that are promising in pharma and healthcare! Click this link to the show notes, transcript, and resources: outcomesrocket.health

Episode #77. The role of marketing capabilities is the focus of this episode, an important topic for marketing leaders and those in their care who need to be continually evolving and abreast of new trends and techniques in our fast-paced industry.  In this episode, Abby and her guest Denise Dewar discuss why marketing capabilities are more than training and upskilling, and how to embed a marketing mindset throughout your whole organisation.  As Global Lead for Marketing Capabilities at Novartis, Denise is responsible for developing strategies and people to become more customer centric.  Denise has 20+ years' experience in consumer and healthcare, and talks about the difference in marketing across the sectors and what the future of marketing means to her. Plus, the commonalities of successful marketing leaders and Denise's career highs and lows.  This podcast is sponsored by Labyrinth Marketing  www.labyrinthmarketing.co.uk  The Whole Marketer podcast is here to support and empower the people behind brands and businesses with the latest technical tools, soft and leadership skills and personal understanding for a fulfilling marketing career and life as a whole. For more info go to www.thewholemarketer.com 

Nina is one of the up-and-coming superstars in biotech. Having just earned her PhD in bioengineering at Stanford in the Sunwoo Lab this summer, she has the scientific horsepower and storytelling ability to make a large impact on drug development, business, and the lives of patients. At the age of 8, Nina was diagnosed with an ovarian teratoma. In some ways, that shifted Nina towards a career in science and a mission to cure cancer. But while she was always interested in science, growing up in the suburbs of New York City enabled her to become world-class oboe and bassoon player as well. But in her words, she chose the research path rather than joining a conservatory because "science is a way to help other people [while] music is fun." At Williams College, she studied mathematics and biology and became interested in the progress going on in the cell therapy space, particularly CAR-T. This is around 2014 when companies like Juno Therapeutics, Novartis, and Kite Pharma were engineering patient T-cells to hone in on lymphomas. With a growing interest in bioengineering and the early clinical successes in CAR-T, Nina was compelled to join the LEAP program at Boston University to study bioengineering with a goal of engineering immune cells to target cancer. After applying to a number of graduate programs, Nina ended up at Stanford. She rotated through 5 labs: Irv Weissman, Garry Nolan, Crystal Mackall, Edgar Engleman, and John Sunwoo. These experiences ended up having a major impact on her research where she was able to have the flexibility to pursue the projects she was excited by in cell therapies and use various tools/methods she picked up from the other 4 groups in her graduate research. Early-on in grad school, her cancer relapsed and she was treated again. One thing about Nina is her grit. She was able to still move forward with her work despite all of this. Truly amazing. Her first project ended up not working out perfectly but taught Nina how to choose problems to work on. Michael Fischbach helps teach a class at Stanford, BioE 395, on this topic that Nina and I would recommend checking out. Her next project focused on studying subtypes of NK cells in tumors and generating functional data to figure out if they are a unique class of immune cells or an artifact of single-cell sequencing. After figuring out how to run an experiment with 1 month of prep, around 4 days of work, and then 3 weeks of data acquisition and analysis (shout-out to Gail for the help), Nina was able to discover a novel functionality of a new NK cell type that resembles ieILC1s, which have potent anti-tumor activity. Once she was able to show the experiment worked, Nina did the harrowing experiment another five times to verify her discovery and did an incredible job to combine various tools to map out new NK cell biology. At the end of the conversation, we discuss her new job as Head of Research at ImmuneBridge and the opportunities she sees in cell therapies. Nina is truly a role model to scientists and cancer survivors everywhere.

Novartis investiert 100 Millionen Franken in den Campus im St. Johann, Novartis baut dort ein neues Zentrum für Biotherapeutika, eine boomende Sparte. Das sei ein Bekenntnis für den Standort Basel, so Novartis. Das neue Zentrum ersetzt bis im Jahr 2026 eine Abteilung auf dem Klybeckareal. Weitere Themen: * Gemeinde Bennwil überlegt sich, Beleuchtung auszuschalten * Mobilitätswoche in Basel

Host: Anisha Dua, MD, MPH Guest: Michael Putman, MD, MSci What are some imaging factors we should consider when monitoring giant cell arthritis (GCA) and the medication prescribed for it? Dr. Anisha Dua is joined by Dr. Mike Putman to explore these factors. Dr. Dua and Dr. Putman are Novartis consultants. 199849 6/22

Episode Summary: In this episode of the L3 Leadership podcast, Ginger discusses her career journey at Southwest, what she learned while working there, and shares her thoughts on work culture. About Ginger: Ginger Hardage retired as Senior Vice President of Culture and Communications at Southwest Airlines after an illustrious 25 years, where she served as a member of the CEO's executive leadership team. At Southwest, Ginger led a team of 150 people responsible for building and sustaining the organization's legendary culture and communications enterprise.In 2017, Ginger launched Unstoppable Cultures, a brand designed to help organizations create and sustain cultures of enduring greatness. Recognized by many as a foremost global authority on building and sustaining organizational culture, Ginger was responsible for the activities at Southwest that nourished the culture and the internal and external communications function. Ginger has received numerous honors throughout her career, including induction into the PublicRelations Hall of Fame, being named as one of Texas' Most Powerful and Influential Women and receiving the prestigious Larry Foster Award for Integrity in Public Communication from the Arthur W. Page Society. PRWeek has named her multiple times to its Top 50 Power list and 50Most Powerful Women in Public Relations. She was named “Legendary Communicator” by Southern Methodist University, Legacy Award honoree by the Plank Center for Leadership, and selected for the James C. Bowling Executive-In-Residence Lecture Series at the University of Kentucky.Ginger currently serves as Global Chairman of the Board for Ronald McDonald House Charities. In Dallas, she serves on the board of The Trinity Park Conservancy and was a past president of the Trinity Commons Foundation. Ginger previously served on advisory boards of Novartis in Basel, Switzerland; The Page Society; Business Civic Leadership Center, an affiliate of the U.S. Chamber of Commerce; Big Brothers and Sisters of Metropolitan Dallas; Southwest Cares; and the Council of Public Relations Firms.Ginger earned a B.A. in advertising/public relations from Texas Tech University and was recognized as an outstanding alumna by the College of Mass Communications at Texas Tech University.Ginger lives in Dallas, TX, and Santa Fe, NM with her husband, Kelly.4 Key Takeaways:1. Ginger recalls how she got her position at Southwest Airlines and grew a team centered around culture and communications.2. She advises emerging leaders to distinguish themselves to grow within their current organization.3. She discusses where her career has gone since departing Southwest Airlines. 4. Ginger talks about what company culture and effective communication mean to her. Quotes From the Episode:“Culture isn't a faucet you can turn on and off.”“I believe that culture, leadership, and communication go hand in hand.”“We have to be authentically ourselves to be authentically happy.”“Leaders cast a long shadow”.Resources Mentioned:Ginger's Masterclass: The FellowshipConnect with Ginger:Website | Twitter | Linkedin | Instagram 

Welcome to Strategy Skills episode 274, an episode with Bill George, former chairman and CEO of Medtronic and currently a professor at Harvard Business School. He has written two of the most enduring leadership classics of all time: Authentic Leadership and True North. Now, Bill has written a new book aimed at the next generation of leaders, the Emerging Leaders Edition of True North, coauthored with millennial entrepreneur Zach Clayton. Get Bill's new book here.   This book is a clarion call to emerging leaders to step up to lead their organizations with their hearts, not just their heads, as authentic leaders who lead with purpose by inspiring and coaching their teammates. It heralds the end of the baby boomer era of Jack Welch, when too many leaders focused on maximizing shareholder value and taking shortcuts rather than building sustainable enterprises to serve all of their stakeholders. Our best hope for a better world is to empower the next generation of emerging leaders – not just those on top – to follow their True North to make this world better for everyone.   The stories in this book, which came from 220 interviews with exceptional leaders, illustrate that most authentic leaders first discovered their True North through their life stories and crucibles, developed self-awareness, and then found their North Star – the purpose of their leadership. Wisdom learned from leaders like Satya Nadella, Mary Barra, Ken Frazier, Indra Nooyi, Ursula Burns, and Hubert Joly will guide emerging leaders at all levels in their development.   Bill joined Medtronic in 1989 as president and chief operating officer, was chief executive officer from 1991-2001, and board chair from 1996-2002. He is currently a senior fellow at Harvard Business School, where he has taught leadership since 2004. He is the author of Discover Your True North and The Discover Your True North Field Book, Authentic Leadership, Seven Lessons for Leading in Crisis, Finding Your True North, and True North Groups. He has served on the boards of Goldman Sachs, ExxonMobil, Novartis, Target, and Mayo Clinic.    He received his BSIE with high honors from Georgia Tech, his MBA with high distinction from Harvard University, where he was a Baker Scholar, and honorary PhDs from Georgia Tech, Mayo Medical School, University of St. Thomas, Augsburg College, and Bryant University.    True North: Leading Authentically in Today's Workplace, Emerging Leader Edition. Bill George & Zach Clayton.   Enjoying our podcast? Get access to sample advanced training episodes here: www.firmsconsulting.com/promo

Learning & Development seems to be constantly evolving but at the same time revisiting and reinventing what has come before. In this episode, we discuss the emerging trends that have their origins in the past and the pioneers that we all need to pay more attention to. KEY TAKEAWAYS Even today, much of what we do in L&D is not evidence-based. This has to change. We are not taking successful methods from the past and reworking them for the modern world. Instead, we are simply rehashing old theories, without looking for evidence that they work. We don´t look back to see who might have done what we are trying to achieve before. You have to understand the jobs of the participants, and do the cognitive task analysis. L&D is not all about delivering learning. They are there to solve problems that are holding the business back Stakeholder management is a vital component of delivering solutions that work. BEST MOMENTS 'There is a big gap between positive endeavour and evidence-based practice.' 'Do it well, or don´t do it 'You need to work with problem analysis teams and then with problem-solving teams.' 'We need to think more holistically ' VALUABLE RESOURCES The Learning And Development Podcast - https://podcasts.apple.com/gb/podcast/the-learning-development-podcast/id1466927523 L&D Masterclass Series: https://360learning.com/blog/ EPISODE RESOURCES You can follow and contact Mirjam via: Twitter: @MirjamN LinkedIn: https://www.linkedin.com/in/mirjamneelen/details/experience/ How Learning Happens by Paul Kirschner - https://www.amazon.co.uk/How-Learning-Happens-Paul-Kirschner/dp/0367184575/ How Teaching Happens by Paul Kirshner - https://www.amazon.co.uk/How-Teaching-Happens-Effectiveness-Practice/dp/1032132086/ Guy Wallace Books - https://www.amazon.co.uk/Guy-W-Wallace/e/B08JQC4C4V?ref=sr_ntt_srch_lnk_1&qid=1662104935&sr=8-1 Joe Harless - https://hptmanualspring16.weebly.com/harless-model.html Donald Clark - https://www.amazon.co.uk/Donald-Clark/e/B08HVS5QSP?ref=sr_ntt_srch_lnk_1&qid=1662105350&sr=8-1 Dr. Jane Bozarth - https://www.amazon.co.uk/Jane-Bozarth/e/B001JS7VKO?ref=sr_ntt_srch_lnk_4&qid=1662105930&sr=8-4 Patti Shank - https://www.amazon.co.uk/s?k=patti+shank&crid=1I6XTHRPN5DBM&sprefix=patti+shank%2Caps%2C123&ref=nb_sb_noss_1 Connie Malamed - https://www.amazon.co.uk/Connie-Malamed/e/B001SQ2JHW?ref=sr_ntt_srch_lnk_1&qid=1662106345&sr=8-1 Mike Taylor - https://mike-taylor.org/   ABOUT THE GUEST Mirjam Neelen Bio Mirjam Neelen is the Head of Global Learning Design and Learning Sciences in Novartis. She is part of a team that redefines how Novartis Associates build competence. With 15 years' industry experience, she has worked in a wide variety of learning design roles in organisations such as Accenture, Google, and Houghton Mifflin Harcourt. ABOUT THE HOST David James  David has been a People Development professional for more than 20 years, most notably as Director of Talent, Learning & OD for The Walt Disney Company across Europe, the Middle East & Africa.  As well as being the Chief Learning Officer at 360Learning, David is a prominent writer and speaker on topics around modern and digital L&D.  CONTACT METHOD  Twitter:  https://twitter.com/davidinlearning/ LinkedIn: https://www.linkedin.com/in/davidjameslinkedin/ L&D Collective: https://360learning.com/the-l-and-d-collective/ Blog: https://360learning.com/blog/ L&D Masterclass Series: https://360learning.com/blog/ See omnystudio.com/listener for privacy information.

With 20+ gene therapy targets in Novartis Gene Therapies' pipeline, President Chris Fox and her team are hyper-focused on newborn screenings as the pathway to helping more and more patients. The company's initial gene therapy, Zolgensma, for spinal muscular atrophy (SMA) has been approved in more than 40 regions and countries and has been used to treat more than 2,300 patients worldwide. Fox details what's next on the commercialization front for the therapy, and she shares advice with Cell & Gene: The Podcast listeners about what it takes to commercialize a therapy.

Darnell Smith is the Founder and CEO of MXXN, a non-alcoholic, cannabis-infused spirits brand that is evolving today's cocktail culture and disrupting the alcohol and cannabis industry.  Darnell is A CPG and alcohol industry veteran and cannabis entrepreneur, innovator and advocate. Prior to founding MXXN and MOJO, Smith was a senior digital transformation lead at Infosys Consulting working with the likes of Adidas, Ralph Lauren, AB InBev, Novartis, GSK, Pfizer, AMEX and more. Prior to that, Smith worked for over a decade in various agency and client side roles focused on innovation and commercialization for the likes of Diageo and Pernod Ricard.

TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Joseph Saseen, PharmD, FCCP, FNLA, Associate Dean for Clinical Affairs, Professor, Department of Clinical Pharmacy and Professor, Department of Family Medicine from the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus about managing statin intolerance. Listen in as they discuss how to evaluate statin-associated muscle pain...and review strategies to help patients take a statin successfully. You'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Andrea Darby Stewart, MD, Associate Director, Family Medicine Residency at Honor HealthAnthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversitySteven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute and the Lewis and Patricia Dickey Chair in Cardiovascular Medicine Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve UniversityJoseph Scherger, MD, MPH, Family Physician, Primary Care 365, Eisenhower HealthCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.Pharmacist's Letter offers CE credit for this podcast. Log in to your Pharmacist's Letter account and look for the title of this podcast in the list of available CE courses.If you're not yet a Pharmacist's Letter subscriber, find out more about our product offerings at trchealthcare.com. Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

Host: Anisha Dua, MD, MPH Guest: Elaine Husni, MD, MPH The risk of developing cancer may be higher in patients with spondyloarthritis, or SpA for short.1-6 What do we need to know about the risk of cancer, as well as other malignancies in these patients? Dr. Anisha Dua joins Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to explore malignancies in SpA. Dr. Dua and Dr. Husni are Novartis consultants. Deng C, Li W, Fei Y, Li Y, Zhang F. Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep. 2016;6:1-6. Gross R, Schwartzman-Morris J, Krathen M, et al. A comparison of malignancy incidence among psoriatic and rheumatoid arthritis patients in a large US cohort. Arthritis Rheumatol. 2014;66(6):1472-1481. Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatology. 2016;152(3):282-290. Moon H-I, Chang H-J, Kim J-E, Ko H-Y, Ann S-H, Min C-K. The association between multiple myeloma and ankylosing spondylitis: a report of two cases. Korean J Hematol. 2009;44(3):182-187. Chang CC, Chang CW, Nguyen PAA, et al. Ankylosing spondylitis and the risk of cancer. Oncol Lett. 2017;14(2):1315-1322. Karmacharya P, Shahukhal …

Drs. Nicholas Farber, Akshay Thomas, and Priya Vakharia join to discuss the September 2022 issue of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered pertain to diabetic retinopathy and relaxing retinectomy surgery.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon, DORC, Genentech, and Regeneron. Dr. Thomas is a consultant for Allergan, Avesis, Bausch and Lomb, and Novartis. Dr. Vakharia is a consultant for Genentech and Bausch and Lomb. Dr. Farber has no disclosuresYou can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

In this episode of Pharma Launch Secrets, Bozidar is joined by Bharti Rai, the former VP of Commercial Acceleration Commercial Operations, Insights, Analytics, Data & Digital at Novartis, and now the SVP and GM of Health Insights, Products, and Solutions at CVS. They discuss the role of data analytics in customer personalization, driving business, and creating a competitive advantage.

Vasanth is a polymath- he's a creative director, but he's also an author, he has an engineering background is a graduate of computer engineering and started his career as a digital consultant. Somehow he saw the light, transitioned to copywriting, and has held numerous jobs with JWT, Wunderman, Edelman, and Sapient-Razorfish.  Vasanth also spent time in the halls of one of the most respected creative departments on the planet- BBDO NY. He worked on the likes of  P&G (Gillette), J&J (Splenda, Lactaid), GE, Mars, and Emirates Airlines.For the past four years, he's been running his shop, The Sunny Side, which aims to disrupt large agencies and make the combination of quality, speed, and price work. It seems to be paying dividends as the agency has picked up business from Sephora, Castrol, Novartis, and P&G.  In our conversation, we talk about his background, career, his work at BBDO, the similarities and differences between Asian markets, and bringing speed and skill to some of the biggest clients in the world. 

Conversamos con Consuelo Urquiza, líder chilena para Ab Inbev en su país, sobre:+ La vida en Viña del Mar y la inspiración de su abuelo+ Personalidad disruptiva y rebelde+ La mentalidad en crecimiento+ El mundo del Talento en Hewlett Packard, Novartis, Kimberly Klark+ La cultura de una gran empresa que crece de forma acelerada+ La verdad cultura en una empresavansa, crea experiencias educativas poderosas con tecnología, trabajamos con más de 540 compañías en América desde 4 frentes:1) CREAR: desarrollamos soluciones edtech para empresas como: cursos virtuales, inducciones, videos, podcasts y mucho más2) FORMAR: a través de una metodología híbrida/blended formamos al talento en las 10K ( 10 competencias clave para el presente y futuro del trabajo) de manera entretenida y aplicable3) GAMIFICAR: diseñamos estrategias de gamificación para alcanzar objetivos de negocio y creamos juegos virtuales para generar un aprendizaje increíble4) HACKEAR: contamos con una Academia de Hackers del Talento para formar a los futuros líderes de Talento Humano de América Latina y crear una comunidad de actores de cambiowww.vansa.coSuscríbete para escuchar Hackers del Talento acá: https://open.spotify.com/show/2YhEwGc4OHlmdOZ3YffvJF?si=HhiZJb2MQCCIFAEOmG0DhA&dl_branch=1Suscríbete al newsletter para impactar tu talento y el de tu empresa acá: https://vansa.co/hackers-del-talento/newsletter-vansa/

John Rossman is a business strategist, operator, and expert on digital transformation, leadership, and business reinvention. As a management advisor and interim executive, he has consulted with some of the best brands across many industries including Novartis, Fidelity Investments, Microsoft, Walmart, and Nordstom. He served as senior innovation advisor at T-Mobile and senior technology advisor to the Gates Foundation. He is the founder of Rossman Partners, Inc, a niche management consulting team and set of trusted partners helping clients compete and win in the digital era. He is an operator and builder whose love is diving into real business problems and customer needs to design actual solutions and business opportunities. He is a former Amazon executive who played a key role in launching the Amazon marketplace business in 2002. He has written three books –  The Amazon Way book series and writes a weekly newsletter The Digital Leader Newsletter on Substack.Episode Links:Web:  www.the-amazon-way.comFacebook: https://www.facebook.com/TheAmazonWayLinkedIn: https://www.linkedin.com/in/john-rossman/Twitter: https://twitter.com/johnerossmanJoey Pinz Conversations Podcast Information: • Website: https://www.joeypinz.com • Link Tree: https://linktr.ee/joeypinz • Music by Tom Izzo: @wahlsinger  https://tomizzomusic.com  Support our podcast:  • Subscribe: https://joeypinzconversations.com/subscribe/ • How much is this podcast worth to you? Consider $5, $10 or $20/mo with Patreon: https://www.patreon.com/joeypinz  • How about a one-time payment?  • What is the episode worth to you? $25/$50/$100/$500 /$1,000/$5,000 with PayPal (one-time): https://www.paypal.com/paypalme/JoePannone Please subscribe/follow to Joey Pinz Discipline Conversations Podcast: • Spotify, Apple, Google, or others.  Please consider rating with 5 stars if you like it. • Apple: https://podcasts.apple.com/us/podcast/joey-pinz-discipline-conversations/id1583997438 • Spotify: https://open.spotify.com/show/69SFwY3XSwcw9qNvElAn10 • Google: https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5idXp6c3Byb3V0LmNvbS8xODI4OTA2LnJzcw • YouTube: https://www.youtube.com/c/JoeyPinzDisciplineConversations?sub_confirmation=1Please follow on social media: @TheJoeyPinz • Instagram: @TheJoeyPinz https://www.instagram.com/TheJoeyPinz  • Twitter: @TheJoeyPinz  https://twitter.com/TheJoeyPinz • Facebook: @TheJoeyPinz https://www.facebook.com/TheJoeyPinz • TikTok:  @TheJoeyPinz  https://www.tiktok.com/@thejoeypinzFinally,  join our newsletter: https://joeypinzconversations.com/#newsletterSupport the show

Hosted by Andrew Keen, Keen On features conversations with some of the world's leading thinkers and writers about the economic, political, and technological issues being discussed in the news, right now. In this episode, Andrew is joined by Bill George, author of True North: Leading Authentically in Today's Workplace. Bill George is the former Chair and CEO of Medtronic and Executive Fellow at Harvard Business School (HBS), where he has taught leadership to MBAs and executives since 2004. He is the author of four bestselling books: Authentic Leadership, True North, Finding Your True North, and 7 Lessons for Leading in Crisis. True North has been recognized as one of the 25 Best Leadership Books of All-Time. He has served on the boards of Goldman Sachs, Mayo Clinic, ExxonMobil, Novartis, and Target. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ophthalmology acquisitions, following the pharma trends, and a move in healthcare that is not technology related. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesAlcon + AerieNovartis + SandozLabcorp + RWJBHAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Lisa Deschamps' story is one of determination and fortitude. She got her start in the life sciences where it begins and ends for many— "carrying the bag" in big pharma sales—then proceeded to crush the odds on her way to the C-suite at Novartis. Today, she's CEO at AviadoBio, a disruptive gene therapy startup prepping an intra-thalamic Frontotemporal Dementia candidate for the clinic with a heavy Series A in its hip pocket. On this episode of the Business of Biotech we get to know Lisa, her company and its therapeutic approach, her advocacy for genetic testing, and how she's applying her determination and fortitude to enabling more women to become life science leaders. 

The Franklin International Core Divided TILI Index ETF (DIVI) aims to deliver a higher dividend yield while minimizing expected tracking error relative to the broad-based parent index. Dina Tang discusses how dividend ETFs can help investor portfolios in a volatile market. She also goes over some of DIVI's top holdings which include Nestle, Novartis, and ASML Holdings. Tune in to find out more.

Senior Editor Annalee Armstrong was doing a pretty routine interview with Genentech's Greg Rippon when she heard what she says was a mea culpa. Genentech wasn't able to recruit the kind of diverse population that would truly reflect the predominance of Alzheimer's in non-white communities. Annalee will discuss what she heard from Rippon about the lack of trial diversity and how Genentech hopes to get it right in the future.  How memorable are diabetes brands? According to a new report out by Phreesia, patients are too overloaded with names to remember. We'll discuss how pharma companies could change their marketing strategy. To learn more about topics in this episode:  Genentech didn't get it right on diversity for critical Graduate Alzheimer's program. They're trying again  Diabetes brand awareness in the doldrums despite plowing big bucks into ad campaigns  Abbott proclaims FDA approval of neurostimulator to treat pain in 6 areas at once  After FDA rejection, Gilead's long-acting HIV med Sunlenca snags first global nod  Third Harmonic, with an old Novartis drug in hand, braves frosty IPO waters in a quick-fire cash grab  Alcon swoops on Aerie, striking $770M buyout to expand eye drug pipeline  Ex-Novartis unit Alcon keeps eye med expansion rolling with $770M pact to snap up Aerie  Alcon scopes out $475M acquisition of glaucoma stent maker Ivantis UPDATED: Teva won't reopen troubled California site, where 300-plus are losing their jobs  We're looking for 2022's Fiercest Women in Life Sciences—closes this week  The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts. See omnystudio.com/listener for privacy information.

Eine Eröffnungsrede lässt die Börsen stillstehen, nicht einmal Amazon lässt die Verluste von Peloton stillstehen und ohne Plug Power werden ab 2025 Gabelstapler von Amazon stillstehen. Außerdem hat Novartis keinen Bock mehr auf Sandoz. Starkes Wachstum, hohe Gewinne, krasse Kunden - Europa hat nicht viele Tech-Perlen, aber Adyen (WKN: A2JNF4) ist eine von ihnen. Wird auch ohne Anleihen schwer? Für Apple scheinbar schon. Diesen Podcast der Podstars GmbH (Noah Leidinger) vom 26.08.2022, 3:00 Uhr stellt Dir die Trade Republic Bank GmbH zur Verfügung. Die Trade Republic Bank GmbH wird von der Bundesanstalt für Finanzaufsicht beaufsichtigt.

25. Trusted to Thrive (with Marie-Claire Ross) Marie-Claire Ross, BA (Hons), is a speaker, facilitator, and mentor. She helps organizations that have previously had toxic leadership and are now transforming into a healthy, trusting culture. Marie-Claire works with companies around the world such as Qantas, PETRONAS, Australian Tax Office, Hamad Medical Corporation (Doha) and Novartis.  She is also the author of Trusted to Thrive: How Leaders Create Connected and Accountable Teams and Transform your Safety Communication.  In this episode: Marie-Claire's company is called Trustologie, this made-up word that she made up to show she focuses on trust, and it implies that it is similar to learning a subject like biology or psychology (but the logie part means something different in Australia where she lives) We talked about the challenges of building trust in teams and why the leader plays such a key role for success. She shared some great research with statistics about teams and trust from a study that Google did a few years ago. Her clients are usually teams that have recently formed or who are going through transition. She recently published her new book called, Trusted to Thrive, which is for leaders who realize who want to get the best performance out of their team, they are in charge of that and to do that they need to create a thriving team culture. Her book is intended to be a guide for leaders to leverage whenever they are struggling with trust on their team. We talked about the practical and smart ways that she discussed visibility in her own book. Marie-Claire's Book Recommendation: Turning Pro To purchase her book: Trusted to Thrive Here is how to contact Marie-Claire and learn more about her work: marie-claireross.com Trustologie on Twitter (@trustologie) Trustologie on Facebook (@trustologie) Marie-Claire Ross on LinkedIn (ln/marieclaireross) Thank you for listening to The Visibility Factor Podcast! Check out my website to order my book and view the  videos/resources for The Visibility Factor book. As always, I encourage you to reach out! You can email me at hello@susanmbarber.com. You can also find me on social media everywhere – Facebook, LinkedIn, and of course on The Visibility Factor Podcast! I look forward to connecting with you! If you liked The Visibility Factor, I would be so grateful if you could subscribe and rate it where you listen to podcasts! It helps the podcast get in front of more people who can learn how to be visible too!   Thank you to the team at Sheep Jam Productions for the amazing support of The Visibility Factor Podcast!

Novartis trennt sich von Sandoz, Vaterschaftsurlaub ist beliebt, Riga beginnt mit Abriss von sowjetischem Siegesdenkmal, E-Autos im Crashtest

Novartis trennt sich von seiner Generika-Sparte Sandoz. 20 Jahre lang war Sandoz Teil des Basler Pharmakonzerns. Novartis will Sandoz aber nicht verkaufen, sondern als eigenständiges Unternehmen ausgliedern. Was verspricht sich das Pharmaunternehmen davon? Weitere Themen: Die Preise für Strom sind gestiegen und werden weiter steigen. Für diejenigen, die Strom produzieren, ist das theoretisch eine vielversprechende Ausgangslage. So auch für den Energiekonzern Alpiq, der 2019 beinahe Konkurs ging. Doch Alpiq warnt: Die Energiemärkte könnte bald noch verrückter spielen. Streubomben sind eine durch ein internationales Abkommen geächtete Waffengattung. Denn sie verursachen viel Leid. Im vergangenen Jahr wurden sie weltweit nur noch in einem einzigen Land eingesetzt, nämlich in der Ukraine. Und zwar grossmehrheitlich durch Russland, wie der jährliche Streubombenbericht dokumentiert.